Company Announcements

Company Announcements

›

Company

Announcements

Stay in the loop

Thank you for subscribing!

Oops! Something went wrong while submitting the form.

Beckley Psytech grows team with new Clinical Operations and Communications hires

We are happy to announce the arrival of Ruth Bateson as Senior Director, Clinical Operations and Charlotte Chorley as Communications Lead.

Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model

Beckley Psytech Announces Partnership With Empatica in Latest Step of Digital Strategy, Designed to Deliver Personalised Patient Care

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey.

Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines With Research Collaboration and Strengthening of Relationship With Lophora ApS

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team

Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress 2022.

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices. Data from Phase 1 will be used to select lead compound for upcoming Phase 2 in treatment resistant depression (TRD).

Beckley Psytech to present at 32nd Annual Oppenheimer Healthcare Conference

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 32nd Annual Oppenheimer Healthcare Conference

Beckley Psytech publishes peer-reviewed paper on 5-MeO-DMT in Journal of Psychopharmacology

Literature review highlights need for further clinical exploration of 5-MeO-DMT

Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials

Training programme to be conducted in partnership with industry-leading educational company, Fluence. Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements.

Beckley Psytech applies for B Corporation status as part of its commitment to have a positive impact on society

B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.

Featured on